Stoddart et al. described one case of potential alemtuzumab-associated TTP that occurred 16 months after alemtuzumab therapy [22], and Bourdin and colleagues reported a patient who developed TTP 45 months after alemtuzumab administration [9]; neither reported use of CIs or mTOR inhibitors. This evidence concerns the gene MTOR and thrombotic thrombocytopenic purpura.